R01DA053659

Optimizing a Bio-Behavioral Intervention to Promote Viral Suppression Among HIV+ People Who Inject Drugs on the U.S.-Mexico Border

7. Project Summary/Abstract

The primary goal of the proposed research is to build an optimized intervention to promote sustained viral suppression among a group of Latinx people who inject drugs and who are living with HIV on the U.S.-Mexico border. We are using the Multiphase Optimization Strategy (MOST), an engineering-inspired framework for designing and building optimized interventions.

The primary aim is to conduct a 2-to-4 factorial design where participants are randomized to zero or up to four intervention conditions. Each condition comprises a different set of intervention components. The four components are receiving (or not receiving) peer support services for medication-assisted treatment (MAT) uptake and persistence, behavioral activation therapy for depression (BAT), life-steps medication adherence program, and patient navigation for HIV care.

The intervention is being implemented at Programa Compañeros, a community-based social service organization in Cuidad Juarez, Chihuahua, Mexico, a city nestled alongside El Paso, Texas. Participants will complete a baseline survey assessment, complete their assigned intervention programs, and then return for 6-, 9-, and 12-month follow-up assessments.

The primary outcome is sustained viral suppression, defined as viral load test results of <400 copies per mL on all 6-, 9-, and 12-month follow-up visits. Results of Aim 1 will yield estimates of the unique impact of each intervention component, as well as each combination of components, on sustained viral suppression. The research team and partners will make decisions about what constitutes the optimized intervention by judging the observed effect sizes and statistical significance against real-world constraints that go into the delivery of this intervention.

The secondary aims are to test theoretical mediators to explain the influence of the intervention components on viral suppression outcome and moderators of this relationship. We will first test the effect each component exerted at the first, 6-month, follow-up assessment, followed by testing characteristics that may modify this relationship.

San Francisco Regents Of The University Of California

TO SUPPORT BASIC AND CLINICAL NEUROSCIENCE, BIOMEDICAL, BEHAVIORAL AND SOCIAL SCIENCE, EPIDEMIOLOGIC, HEALTH SERVICES AND HEALTH DISPARITY RESEARCH. TO DEVELOP NEW KNOWLEDGE AND APPROACHES RELATED TO THE PREVENTION, DIAGNOSIS, TREATMENT, ETIOLOGY, AND CONSEQUENCES OF DRUG ABUSE AND ADDICTION, INCLUDING HIV/AIDS. TO SUPPORT RESEARCH TRAINING AND RESEARCH SCIENTIST DEVELOPMENT. TO SUPPORT DISSEMINATION OF RESEARCH FINDINGS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) LEGISLATION IS INTENDED TO EXPAND AND IMPROVE THE SBIR PROGRAMS TO EMPHASIZE AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF TECHNOLOGY DEVELOPED THROUGH FEDERAL SBIR RESEARCH AND DEVELOPMENT, INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN THE SBIR PROGRAM. THE LEGISLATION INTENDS THAT THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.

93.279 - Drug Abuse and Addiction Research Programs

National Institute on Drug Abuse (NIDA) [HHS - NIH]

San Francisco, California 94143 United States

Single Zip Code

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) (PAR-19-212)

Amendment Since initial award the total obligations have increased 386% from $670,807 to $3,260,828.